CLINICAL_TRIALS
withdrawal
· 2016-11-07
Clinical Trial Update: A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) [Phase 2]
Summary
A Phase 2 trial of MK-4827 (niraparib) for mantle cell lymphoma has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tesaro, Inc. | Conditions: Lymphoma, Mantle-Cell | Phase 2 | Status: WITHDRAWN